[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597811":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":68,"centralContacts":71,"locations":79,"responsibleParty":98,"collaborators":11,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":11,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":11,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":11,"overallStatus":82,"whyStopped":11,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,16,20,23,26,31],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1","EXPERIMENTAL",null,[13,14,15],"Drug: Xanomeline\u002FTrospium Chloride Capsule","Drug: Xanomeline Enteric Capsule","Drug: Trospium Chloride",{"label":17,"type":10,"description":11,"interventionNames":18},"Part 2",[13,14,19],"Drug: Xanomeline MR",{"label":21,"type":10,"description":11,"interventionNames":22},"Part 3a",[13,14],{"label":24,"type":10,"description":11,"interventionNames":25},"Part 3b",[13,14,19],{"label":27,"type":10,"description":11,"interventionNames":28},"Part 4a",[13,29,30],"Drug: Xanomeline","Drug: Placebo",{"label":32,"type":10,"description":11,"interventionNames":33},"Part 4b",[13,29,30],[35,43,49,55,60,65],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DRUG","Xanomeline\u002FTrospium Chloride Capsule","Specified dose on specified days",[9,17,21,24,27,32],[41,42],"BMS-986510","KarXT",{"type":36,"name":44,"description":38,"armGroupLabels":45,"otherNames":46},"Xanomeline Enteric Capsule",[9,17,21,24],[47,48],"BMS-986519","KarX-EC",{"type":36,"name":50,"description":38,"armGroupLabels":51,"otherNames":52},"Trospium Chloride",[9],[53,54],"BMS-986520","KarT",{"type":36,"name":56,"description":38,"armGroupLabels":57,"otherNames":58},"Xanomeline MR",[17,24],[47,59],"KarX-MR",{"type":36,"name":61,"description":38,"armGroupLabels":62,"otherNames":63},"Xanomeline",[27,32],[47,64],"KarX",{"type":36,"name":66,"description":38,"armGroupLabels":67,"otherNames":11},"Placebo",[27,32],[69],{"name":5,"affiliation":5,"role":70},"STUDY_DIRECTOR",[72,77],{"name":73,"role":74,"phone":75,"phoneExt":11,"email":76},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":78,"role":74,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[80],{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":93,"contacts":94},"Quotient Sciences","RECRUITING","Nottingham","Nottinghamshire","NG1 6JS","United Kingdom","UK",{"type":89,"coordinates":90},"Point",[91,92],-1.15047,52.9536,{"lat":92,"lon":91},[95],{"name":96,"role":74,"phone":97,"phoneExt":11,"email":11},"Philip Evans, Site 0001","4401159749000",{"type":99,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100597811","phase-1-a-study-to-evaluate-novel-karx-and-kart-prototypes-versus-the-karxt-and-karx-ec-reference-following-single-doses-and-to-explore-the-effect-of-food-after-multiple-doses-of-selected-prototypes-in-healthy-adult-participants-100597811",false,"NCT07063342","A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses","Phase 1, 4-Part, Open-label (Parts 1 to 3) and Double-blind (Part 4) Study to Evaluate the Pharmacokinetics of Novel KarX (BMS-986519) and KarT (BMS-986520) Prototypes Versus the KarXT (BMS-986510) and KarX-EC (BMS-986519) Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants, and to Evaluate Alternative Formulations of KarX (BMS-986519) and KarXT (BMS-986510) Following Single and Multiple Ascending Doses in Healthy Adult Participants","Inclusion Criteria:\n\n* BMI between 18.0 kg\u002Fm2 to 32.0 kg\u002Fm2, inclusive, at screening.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"ALL","18 Years","55 Years",{"count":112,"type":113},236,"ESTIMATED","INTERVENTIONAL",[116],"PHASE1","The purpose of this study is to evaluate novel KarX and KarT prototypes versus the KarXT and KarX-EC reference following single doses, to explore the effect of food after multiple doses of selected prototypes, and to evaluate alternative formulations of KarX and KarXT following single and multiple ascending doses in healthy adult participants.",[119],"Healthy Volunteers","2026-08-13",{"date":122,"type":123},"2026-08-17","ACTUAL",{"date":125,"type":123},"2025-06-27",{"date":127,"type":113},"2027-03-29",{"name":5,"class":6},1]